ArticleHereditas2026
Protective effect of Saikosaponin D modulating endoplasmic reticulum stress mediated by TLR4/MyD88/NF-κB/NLRP3 pathway on cholestatic liver injury.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveCholestatic liver injury (CLI) has lacked a potent treatment due to its incompletely understood pathogenesis. Saikosaponin D (SSD), the main active ingredient of the traditional Chinese medicine Bupleuri Radix, has significant anti-inflammatory and hepatoprotective effects and inhibits hepatic fibrosis. This study specifically investigated the protective effects of SSD in CLI and its related mechanisms.
methodsIn bile duct ligation (BDL)-induced CLI in mice, the protective effect of SSD was assessed by serum biochemical index analysis, HE staining of liver tissue, Sirius red staining, immunohistochemistry and ELISA. Bile acid-induced human HepG2 cell line was taken to study the protective effect and potential mechanism of SSD against CLI in vitro. TLR4/MyD88/NF-κB/NLRP3 pathway-related proteins in mouse liver tissues or HepG2 cells were detected by Western blot or immunofluorescence.
resultsSSD dose‑dependently improved liver function and reduced hepatocyte necrosis, collagen deposition, and apoptosis. It attenuated oxidative stress injury, inflammatory responses, and endoplasmic reticulum stress (ERS) in BDL mice. SSD also mitigated bile acid‑induced injury and ERS in HepG2 cells. Moreover, SSD suppressed the activation of the TLR4/MyD88/NF‑κB/NLRP3 pathway. The TLR4 inhibitor TAK‑242, similar to SSD, ameliorated bile acid‑induced HepG2 cell injury and ERS, whereas the TLR4 agonist LPS counteracted the protective effects of SSD and its inhibition of ERS in bile acid‑stimulated HepG2 cells.
conclusionSSD attenuates CLI, an effect that may be associated with the suppression of the TLR4/MyD88/NF‑κB/NLRP3 pathway and the subsequent inhibition of ERS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.